Our Offering
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Services and Support Solutions
ACHIEV™
Our Company
About Us
Purpose and Strategy
Leadership
History
Locations
Site Tours
Partnering with Us
Events
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
Podcast
Journalist Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Reporting and Presentations
Consensus and Analysts
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Environment
People and Society
Compliance and Integrity
Responsible Sourcing
Global Quality
Sustainability Report
Careers
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Our Offering
Corporate
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Services and Support Solutions
ACHIEV™
Our Company
Corporate
About Us
Purpose and Strategy
Leadership
History
Locations
Site Tours
Partnering with Us
Events
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
Podcast
Journalist Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Reporting and Presentations
Consensus and Analysts
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Environment
People and Society
Compliance and Integrity
Responsible Sourcing
Global Quality
Sustainability Report
Careers
Corporate
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Corporate
Biologics News Archive
Home
News and Media
News Releases
Biologics News Archive
Filter Results
Filter
Filter by:
News Category
General (70)
Partnerships (35)
Media Advisory (14)
Acquisitions (3)
New Products (3)
New Technologies (3)
Financials (2)
Ad hoc (1)
Year
2024 (9)
2023 (12)
2022 (6)
2021 (18)
2020 (20)
2019 (10)
2018 (10)
2017 (9)
2016 (8)
2015 (2)
2014 (4)
Language
English (108)
English
X
Showing 1‐10 of 108
Biologics
22 Oct 2024
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The...
Biologics
15 Oct 2024
Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)
Expansion adds a new facility to Lonza’s Drug Product Services (DPS) footprint, supporting clinical and commercial projects through additional quality control (QC) and...
Biologics
01 Oct 2024
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the...
Biologics
26 Sep 2024
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s disease Extension to...
Biologics
05 Sep 2024
Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH)
Expansion adds manufacturing capacity for clinical and commercial supply of microbially-produced biologics The facility is now GMP-qualified for manufacturing...
Biologics
15 Aug 2024
UK Government Supports Lonza’s Expansion Plans
Lonza has purchased a plot in Thames Valley Park, with a view to relocating and expanding its primary UK-based Biologics site over the next decade This proposed new site would...
Biologics
04 Apr 2024
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approved Sabirnetug is the first monoclonal antibody...
Biologics
05 Mar 2024
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer
First time GMP manufacturing of a therapeutic IgE antibody has been achieved at scale GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC)...
Biologics
30 Jan 2024
Lonza and Oxford Nanopore to Collaborate on Novel Test to Accelerate Analysis of mRNA Products
Collaboration aims to commercialize a Current Good Manufacturing Practice (cGMP) validated test to enable advanced and innovative analysis for multiple critical quality...
Biologics
14 Nov 2023
Lonza Launches GS Effex® Cell Line for the Development of Therapeutic Antibodies with Increased Potency
New cell line designed to help overcome challenges in immunotherapy research and development related to the need for antibody therapeutics to have increased potency Derived...
Cookie Settings